Lianchuan Bio closes RMB115m Series B round

Lianchuan Bio recently announced the completion of a total of 115 million yuan in a Series B financing round.
This round of financing was led by Hangzhou Heda Bio-Pharmaceutical Venture Partnership, with participation from Beijing Junchuan Capital, Hangzhou Taimeng Investment, as well as existing investors Sinowisdom, ZSVC and Crestvalue.

Lianchuan Bio recently announced the completion of a total of 115 million yuan in a Series B financing round.

This round of financing was led by Hangzhou Heda Bio-Pharmaceutical Venture Partnership, with participation from Beijing Junchuan Capital,Hangzhou Taimeng Investment, as well as existing investors Sinowisdom, ZSVC and Crestvalue.

Proceeds from this round of financing will be used for the research and development of the proprietary gene capture platform and gene synthesis platform, as well as its technology translation and market development in the field of clinical genetic testing.

Lianchuan Bio, founded in 2006, is a genomics and precision medicine company, which has built a production base for genetic testing reagents in line with national GMP standards and has passed ISO13485 quality system certification.

The company has an international R&D center in Houston, USA. Its proprietary VariantPro™ gene capture technology is the first in the world to simplify the gene capture process from a multi-step process to one step, significantly reducing the complexity of clinical applications of NGS.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/06/30/lianchuan-bio-closes-rmb115m-series-b-round/.

Leave a Reply

Please Login to Comment